Global Overview of the Market for Spectroscopy Devices for Monitoring Patient Glucose Levels – ResearchAndMarkets.com

The “Spectroscopy Devices for Monitoring Patient Glucose Levels” report has been added to ResearchAndMarkets.com’s offering.

Noninvasive monitors that can measure analyte levels accurately and reliably have the capability to improve disease control and patient wellbeing.

By integrating the sensing element, electronics, and a power source in a single package, noninvasive monitors are creating new options for caregivers and their patients.

Signal processing improvements – including improved signal-to-noise ratios and interference filtering – will continue to be critical to the commercialization prospects of noninvasive monitors.

Spectroscopic Devices Glucose Measurement – What You Will Learn

  • What are the noninvasive sensing and monitoring technologies that are being pursued, who are the players behind them, and what is their development status?
  • What are the key noninvasive spectroscopic monitoring device design issues and evolving market factors?
  • What is the global market potential for optical monitors today? What will it be in 2024?
  • What will be the likely impact of the availability of commercial noninvasive sensing technology and devices on disease management markets?
  • Who are the market participants in the noninvasive monitoring sector? What are their technologies, product development activities and business strategies?
  • What will be the impact of economic, technology, and regulatory factors on the commercial potential of spectroscopic device patient monitors?

Key Topics Covered:

  • Executive Summary
  • Glucose Sensing Market Overview
  • Monitoring Glucose Levels
  • Key Factors in Patient Compliance
  • Market Drivers
  • Industry Alignment and Competitive Landscape
  • Noninvasive Glucose Measurement Design Factors
  • Measuring Glucose in Interstitial Fluid
  • Patient/User Interface
  • Reliability
  • Data Collection & Reporting
  • Commercial Track NGM Technologies
  • Spectroscopy
  • Raman
  • Infrared
  • Reverse Iontophoresis
  • Continuous Glucose Monitoring
  • Near-term Noninvasive Glucose Measurement Device Analysis
  • Optical Data Collection
  • Direct Analyte Measurement
  • Multimode Sensing
  • Forecasts
  • Important Private Research Programs
  • Asia
  • Soompo Japan Research Institute
  • Toyama Medical And Pharmaceutical University (Japan)
  • North America
  • Juvenile Diabetes Research Foundation (USA)
  • Juvenile Diabetes Research Foundation (USA)
  • Europe
  • Medical University of Graz (Austria)
  • Medical Research Foundation (The Netherlands)
  • Commercialization Factors
  • Calibration Frequency
  • Accuracy & Precision
  • Sensitivity
  • Sensor Technology & Signal Processing Advances
  • Market Factors
  • Regulations
  • FDA
  • EMEA
  • Asia (Japan)
  • Clinical Trials
  • Company Profiles

For more information about this report visit here.

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."